Role of antimicrobial agents in the management of exacerbations of COPD.

Sat Sharma, Nicholas Anthonisen
{"title":"Role of antimicrobial agents in the management of exacerbations of COPD.","authors":"Sat Sharma, Nicholas Anthonisen","doi":"10.2165/00151829-200504030-00001","DOIUrl":null,"url":null,"abstract":"<p><p>Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a common occurrence and characterize the natural history of the disease. Over the past decade, new knowledge has substantially enhanced our understanding of the pathogenesis, outcome and natural history of AECOPD. The exacerbations not only greatly reduce the quality of life of these patients, but also result in hospitalization, respiratory failure, and death. The exacerbations are the major cost drivers in consumption of healthcare resources by COPD patients. Although bacterial infections are the most common etiologic agents, the role of viruses in COPD exacerbations is being increasingly recognized. The efficacy of antimicrobial therapy in acute exacerbations has established a causative role for bacterial infections. Recent molecular typing of sputum isolates further supports the role of bacteria in AECOPD. Isolation of a new strain of Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae was associated with a considerable risk of an exacerbation. Lower airway bacterial colonization in stable patients with COPD instigates airway inflammation, which leads to a protracted self-perpetuating vicious circle of progressive lung damage and disease progression. A significant proportion of patients treated for COPD exacerbation demonstrate incomplete recovery, and frequent exacerbations contribute to decline in lung function. The predictors of poor outcome include advanced age, significant impairment of lung function, poor performance status, comorbid conditions and history of previous frequent exacerbations requiring antibacterials or systemic corticosteroids. These high-risk patients, who are likely to harbor organisms resistant to commonly used antimicrobials, should be identified and treated with antimicrobials with a low potential for failure. An aggressive management approach in complicated exacerbations may reduce costs by reducing healthcare utilization and hospitalization.</p>","PeriodicalId":87162,"journal":{"name":"Treatments in respiratory medicine","volume":"4 3","pages":"153-67"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100764/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Treatments in respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2165/00151829-200504030-00001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a common occurrence and characterize the natural history of the disease. Over the past decade, new knowledge has substantially enhanced our understanding of the pathogenesis, outcome and natural history of AECOPD. The exacerbations not only greatly reduce the quality of life of these patients, but also result in hospitalization, respiratory failure, and death. The exacerbations are the major cost drivers in consumption of healthcare resources by COPD patients. Although bacterial infections are the most common etiologic agents, the role of viruses in COPD exacerbations is being increasingly recognized. The efficacy of antimicrobial therapy in acute exacerbations has established a causative role for bacterial infections. Recent molecular typing of sputum isolates further supports the role of bacteria in AECOPD. Isolation of a new strain of Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae was associated with a considerable risk of an exacerbation. Lower airway bacterial colonization in stable patients with COPD instigates airway inflammation, which leads to a protracted self-perpetuating vicious circle of progressive lung damage and disease progression. A significant proportion of patients treated for COPD exacerbation demonstrate incomplete recovery, and frequent exacerbations contribute to decline in lung function. The predictors of poor outcome include advanced age, significant impairment of lung function, poor performance status, comorbid conditions and history of previous frequent exacerbations requiring antibacterials or systemic corticosteroids. These high-risk patients, who are likely to harbor organisms resistant to commonly used antimicrobials, should be identified and treated with antimicrobials with a low potential for failure. An aggressive management approach in complicated exacerbations may reduce costs by reducing healthcare utilization and hospitalization.

抗菌药物在慢性阻塞性肺病恶化治疗中的作用。
慢性阻塞性肺疾病(AECOPD)的急性加重是一种常见病,也是该病自然病史的特征。在过去的十年中,新知识大大提高了我们对 AECOPD 的发病机制、结果和自然病史的认识。病情加重不仅会大大降低这些患者的生活质量,还会导致住院、呼吸衰竭和死亡。病情加重是慢性阻塞性肺病患者消耗医疗资源的主要成本驱动因素。虽然细菌感染是最常见的致病因素,但病毒在慢性阻塞性肺病恶化中的作用也日益得到认可。抗菌疗法在急性加重期的疗效确定了细菌感染的致病作用。最近对痰分离物进行的分子分型进一步证实了细菌在 AECOPD 中的作用。分离到流感嗜血杆菌、白喉摩拉菌或肺炎链球菌的新菌株与病情加重的风险相当大。病情稳定的慢性阻塞性肺病患者的下气道细菌定植会引发气道炎症,从而导致肺损伤和疾病进展的长期自我循环。相当一部分因慢性阻塞性肺病加重而接受治疗的患者无法完全康复,频繁的病情加重会导致肺功能下降。预示疗效不佳的因素包括高龄、肺功能明显受损、表现不佳、合并症以及既往频繁恶化的病史,需要使用抗菌药物或全身性皮质类固醇。这些高危患者很可能携带对常用抗菌药物产生耐药性的病菌,因此应识别出这些患者,并使用失败可能性较低的抗菌药物进行治疗。对复杂的病情加重采取积极的治疗方法,可以减少医疗使用和住院治疗,从而降低成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信